Is this FDA enforcement data for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has Xiamen Kang Zhongyuan Biotechnology Co., Ltd. had?

Argus HQ has recorded 15 FDA events for Xiamen Kang Zhongyuan Biotechnology Co., Ltd.: 0 warning letters, 15 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.?

The most recent FDA event Argus HQ has on file for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. is dated 2026-04-22, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Xiamen Kang Zhongyuan Biotechnology Co., Ltd. is observed, this page's event count and history update automatically.

FDA Actions Against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.

At a glance: Argus HQ has recorded 15 FDA events for Xiamen Kang Zhongyuan Biotechnology Co., Ltd.: 0 warning letters, 15 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-04-22 to 2026-04-22. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	15
Warning letters	0
Recalls	15
Approval records	0
Form 483 inspection citations	0
Most recent action	April 22, 2026

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Xiamen Kang Zhongyuan Biotechnology Co., Ltd. has 15 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Enforcement history

On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: QC Quality Choice, Menthol-Cough Suppressant Oral Anesthetic, Cough Drops, Sugar… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: QC Quality Choice, Menthol-Cough Suppressant Oral Anesthetic, Cough Drops, Menth… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: QC Quality Choice, Menthol- Cough Suppressant Oral Anesthetic, Cough Drops, Cher… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: QC Quality Choice, Pectin Oral Demulcent, Throat Soothing Drops, Creamy Strawber… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: MGC Health, Menthol- Cough Suppressant, Oral Anesthetic, Cough Drops, Honey Lemo… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: QC Quality Choice, Menthol- Cough Suppressant Oral Anesthetic, Cough Drops, Suga… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: exchange select, Menthol- Cough Suppressant Oral Anesthetic, Cough Drops, Mentho… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Class II recall: exchange select, Menthol -Cough Suppressant Oral Anesthetic, Honey Lemon Flavor… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-22, Argus HQ recorded a FDA recall for Xiamen Kang Zhongyuan Biotechnology Co., Ltd., rated "high" severity in Argus HQ's classification: Xiamen Kang.

Frequently asked questions

Is this FDA enforcement data for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has Xiamen Kang Zhongyuan Biotechnology Co., Ltd. had?: Argus HQ has recorded 15 FDA events for Xiamen Kang Zhongyuan Biotechnology Co., Ltd.: 0 warning letters, 15 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.?: The most recent FDA event Argus HQ has on file for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. is dated 2026-04-22, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Xiamen Kang Zhongyuan Biotechnology Co., Ltd. automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Xiamen Kang Zhongyuan Biotechnology Co., Ltd. is observed, this page's event count and history update automatically.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Actions Against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.. Digital Empire LLC. Retrieved from https://argushq.ai/company/xiamen-kang-zhongyuan-biotechnology-co-ltd

MLA

"FDA Actions Against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/xiamen-kang-zhongyuan-biotechnology-co-ltd.

Chicago

Argus HQ Research. "FDA Actions Against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/xiamen-kang-zhongyuan-biotechnology-co-ltd.

BibTeX

@misc{argushq_argushq_ai_company_xiamen_kang_zhongyuan_biotechnology_co_ltd_2026,
  title = {FDA Actions Against Xiamen Kang Zhongyuan Biotechnology Co., Ltd.},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/xiamen-kang-zhongyuan-biotechnology-co-ltd},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗